REG - GSK PLC - Director/PDMR Shareholding

GSKAnnouncement

28/04/2023 17:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230428:nRSb9473Xa&default-theme=true

RNS Number : 9473X  GSK PLC  28 April 2023

GSK plc (the 'Company')

 

2023 Performance Share Plan Award - Ms J Brown, CFO Designate

2023 Performance Share Plan Award

 

On 27 April 2023, the Company granted conditional share awards to Ms Julie
Brown, a Person Discharging Managerial Responsibilities ('PDMR') under the
GlaxoSmithKline 2017 Performance Share Plan ('the Plan'). The Plan was
approved by shareholders on 4 May 2017 and allows a performance-related
opportunity in the form of conditional awards to be granted to senior
executives in the Group, including Executive Directors and other PDMRs.

 

Under the terms of the Plan, conditional awards are granted over a specific
number of Ordinary Shares or American Depositary Shares ('ADSs'), and the
percentage of awards that ultimately vests is dependent on the level of
achievement against performance targets set by the Remuneration Committee.

 

28 April 2023

 

Notes

 

1.  See the announcement released on 14 February 2023 ('2023 Performance
Share Plan Award and 2023 Performance Measures') for details of the 2023
performance measures.

 

2.   To the extent that each element of a conditional award does not vest at
the end of the three-year performance period, it will lapse.

 

3.   The Award granted to Ms Brown is over Ordinary Shares.

 

4.   Dividends will accrue on the conditional award of Ordinary Shares
during the performance period but will only vest to the extent that the award
vests at the end of the performance period. These dividends are not included
in the figures below.

 

5.   The award is subject to an additional vesting period of two years (the
'Holding Period') from the normal vesting date, i.e. five years in
total.  During the additional Holding Period, the relevant Ordinary Shares
would only be forfeited in the event that the Executive Director was
terminated for cause, and the Ordinary Shares will continue to carry rights to
dividend equivalents.

 

Transaction notification

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Ms J Brown
 b)  Position/status                          CFO Designate
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                A conditional award of Ordinary Shares under the Company's 2017 Performance
                                              Share Plan
 c)  Price(s) and volume(s)                                        Price(s)             Volume(s)
                                                                   £14.422              264,026

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2023-04-27
 f)  Place of the transaction                 N/A

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHSEAFIAEDSEIL